Medical Equipment

Global Drug Eluting Stent Industry Insights: Key Trends and Growth Estimates

February 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Drug Eluting Stent Market expected to reach by 2030?

The drug eluting stent market size has experienced substantial growth in recent years. It is projected to expand from $8.26 billion in 2025 to reach $8.94 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical increase in the market can be attributed to factors such as the rising prevalence of coronary artery disease, an increase in percutaneous coronary intervention procedures, the growing incidence of lifestyle-related cardiovascular conditions, the expansion of cardiac catheterization labs, and improved clinical outcomes when compared to bare-metal stents.

The drug eluting stent market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $11.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This expansion over the forecast period is fueled by factors such as an expanding aging demographic, a heightened need for minimally invasive cardiac procedures, increasing knowledge of advanced stent innovations, the proliferation of specialized cardiac clinics, and greater spending on cardiovascular healthcare. Significant developments expected during this period involve the increasing embrace of biodegradable polymer stents, a growing inclination towards polymer-free drug-eluting stents, their expanded application in intricate coronary procedures, a move towards sustained restenosis prevention, and a heightened call for better drug release management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Drivers Are Driving Adoption Within The Drug Eluting Stent Market?

The increasing occurrence of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD) is characterized by the constriction or obstruction of coronary arteries due to plaque accumulation, which can result in serious health issues like heart attacks or angina. This rise in coronary heart disease is attributed to factors such as inactive living, inadequate nutritional habits, an expanding elderly demographic, and improved diagnostic understanding. Drug-eluting stents (DES) offer advantages in treating coronary heart disease by efficiently clearing narrowed or obstructed coronary arteries and administering drugs to inhibit restenosis, or the re-narrowing of the artery. For example, the National Center for Biotechnology Information, a US governmental entity, reported in August 2025 that cardiovascular disease is expected to grow substantially from 2025 to 2050, with its prevalence increasing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, ultimately causing an estimated 35.6 million cardiovascular deaths in 2050, up from 20.5 million in 2025. This escalating burden of coronary heart disease is consequently anticipated to stimulate growth within the drug-eluting stent market.

What Segments Are Included Within The Drug Eluting Stent Market?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

What Long-Term Trends Are Expected To Shape The Future Of The Drug Eluting Stent Market?

Leading companies within the drug eluting stent market are prioritizing the creation of innovative products, such as low-profile, high-flexibility stents, to enhance deliverability in intricate coronary anatomies and improve patient outcomes. A low-profile, high-flexibility stent refers to a drug eluting stent engineered with a reduced crossing profile and heightened flexibility, allowing it to navigate narrow, tortuous, or calcified coronary arteries with greater ease while maintaining effective drug delivery to prevent restenosis. As an illustration, in May 2024, Abbott Laboratories, a U.S.-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra showcases a novel stent design that provides best-in-class deliverability, with significantly reduced crossing force when compared to competitors. It also incorporates a thinner balloon and an optimized MULTI LINK structure to enhance flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Moreover, it offers a wide expansion range, permitting precise treatment even when vessel diameters vary markedly along the lesion—empowering interventional cardiologists to address complex, calcified, or challenging-to-reach lesions with improved precision and safety.

Who Are The Major Companies Operating In The Drug Eluting Stent Market?

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Drug Eluting Stent Market?

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Drug Eluting Stent Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2026, By The Business Research Company

Vascular Stent Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Bioabsorbable Stents Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Self Expanding Stents Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-expanding-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795